The development of acute-on-chronic liver failure (ACLF) in patients with liver cirrhosis is associated with high mortality rates. Renal failure is the most significant organ dysfunction that occurs in ACLF. So far there are no biomarkers predicting ACLF. We investigated whether cystatin C (CysC) and neutrophil gelatinase-associated lipocalin (NGAL) can predict development of renal dysfunction (RD), hepatorenal syndrome (HRS), ACLF, and mortality. We determined the plasma levels of CysC and NGAL in 429 patients hospitalized for acute decompensation of cirrhosis in the EASL-CLIF Acuteon-Chronic Liver Failure in Cirrhosis (CANONIC) study. The patients were followed for 90 days. Patients without RD or ACLF at inclusion but with development of either had significantly higher baseline concentrations of CysC and NGAL compared to patients without. CysC, but not NGAL, was found to be predictive of RD (odds ratio, 9.4; 95% confidence interval [CI], 1.8-49.7), HRS (odds ratio, 4.2; 95% CI, 1.2-14.8), and ACLF (odds ratio, 5.9; 95% CI, 1.3-25.9). CysC at day 3 was not found to be a better predictor than baseline CysC. CysC and NGAL were both predictive of 90-day mortality, with hazard ratios for CysC of 3.1 (95% CI, 2.1-4.7) and for NGAL of 1.9 (95% CI, 1.5-2.4). Conclusion: Baseline CysC is a biomarker of RD, HRS, and ACLF and an independent predictor of mortality in patients with acutely decompensated liver cirrhosis, though determining CysC at day 3 did not provide any benefit; while NGAL is also associated with short-term mortality, it fails to predict development of RD, HRS, and ACLF. Baseline CysC may help to identify patients at risk earlier and improve clinical management. (HEPATOLOGY 2017;66:1232-1241 P atients with liver cirrhosis often present with an acute decompensation such as ascites, hepatic encephalopathy, or bacterial infection. Moreau et al. showed that patients with acute decompensation have a rather good short-term prognosis, with a 28-day mortality probability of 1.9%.
P atients with liver cirrhosis often present with an acute decompensation such as ascites, hepatic encephalopathy, or bacterial infection. Moreau et al. showed that patients with acute decompensation have a rather good short-term prognosis, with a 28-day mortality probability of 1.9%. (1) Presence or development of acute-on-chronic liver failure (ACLF), as defined by Moreau et al., increases the 28-day mortality rate to around 30%. Among patients with ACLF, renal failure is the most frequent organ failure, occurring in more than 50% of cases. Moreover, subgroup analysis showed that renal failure is associated with a worse prognosis than any other single organ failure. Renal failure in patients with cirrhosis has a devastating impact on prognosis, with a 1-month mortality rate around 50%. (2) (3) (4) (5) The most severe form of renal dysfunction (RD) is hepatorenal syndrome type 1 (HRS), reducing the 3-month survival probability to less than 15%. (6, 7) In order to improve management of acute decompensation in cirrhosis, identifying patients with a high risk of exhibiting RD and ACLF within the next days or weeks could be very useful. A reliable predictor would offer the possibility of making important therapeutic decisions early on, such as listing for transplantation, and provide a window to focus on optimized treatment in order to prevent the deterioration of renal function.
Serum creatinine (Crea), the most commonly used marker of renal function, has several limitations in patients with liver cirrhosis. Synthesis of Crea is typically reduced in these patients, due to muscle wasting and decreased protein intake. (8, 9) Thus, serum Crea tends to overestimate the actual renal function. Moreover, in view of the limited sensitivity of Crea for detecting small changes in glomerular filtration rate (GFR), it is not a promising predictor of deterioration of renal function in patients with liver cirrhosis.
Two renal function markers currently under investigation are cystatin C (CysC) and neutrophil gelatinase-associated lipocalin (NGAL). There is persuasive evidence that plasma levels of either marker can function as a biomarker of early RD in several clinical situations. (10) (11) (12) (13) (14) After renal injury, an increase of either marker in plasma can be detected earlier than that of Crea, and estimations of GFR based on CysC are more accurate than Crea-based formulas. (15) (16) (17) (18) Moreover, both NGAL and CysC are less affected than Crea by factors which are common in patients with liver cirrhosis, like muscle wasting, reduced protein diet, and high bilirubin levels. (9, (19) (20) (21) (22) Hence, both might be useful markers for the prognosis and care of patients with liver cirrhosis.
There are some studies investigating CysC and NGAL as markers of GFR in liver cirrhosis, but few data are available regarding the prediction of acute deterioration of patients with cirrhosis. For example, De Souza et al. evaluated over 200 patients awaiting liver transplantation and found that CysC-based equations more precisely determined the GFR than Creabased equations. (23) This was confirmed in various groups of patients with liver cirrhosis. (24, 25) Furthermore, previous small studies suggested CysC as a predictor for HRS and mortality. (26, 27) In a small cohort of 49 patients, CysC-based estimations of GFR were predictive for overall survival. (28) As with CysC, there are several studies which indicate NGAL as a valuable marker of the GFR in cirrhosis. (11, 29) In a study of 34 patients plasma NGAL levels as well as CysC-based GFR estimations were predictive for development of RD within the next 48 hours. (30) Moreover, plasma levels of NGAL were significantly higher in patients with ACLF than in patients without. (31) Altogether those studies indicate that CysC and NGAL could be useful biomarkers in patients with liver cirrhosis. However, neither marker has been investigated as a predictor of clinical deterioration in a large and well-characterized study population. Thus, the purpose of the present study was to evaluate the potential role of CysC and NGAL in predicting development of the newly defined ACLF, RD, and HRS as well as the probability of survival in patients with acute
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Participants and Methods

STUDY POPULATION
The study population comprised patients who were included in the CANONIC study, as detailed. (1) Informed consent in writing was obtained from each patient. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The CANONIC study had 29 participating liver units in eight European countries. It was initiated by the European Association for the Study of the Liver-Chronic Liver Failure Consortium with the purpose of developing a reliable definition of the syndrome of "acute-onchronic liver failure" in order to identify patients with a high risk of short-term mortality. The CANONIC study enrolled patients who were hospitalized for an acute decompensation of liver cirrhosis.
For the present investigation we selected all patients who had continuous study surveillance and blood sampling after inclusion (study visits on days 1, 2, 3-7, 8-14, 15-21, and [22] [23] [24] [25] [26] [27] [28] . This resulted in a total number of 429 patients with plasma samples available for determination of CysC, NGAL, and Crea, respectively. Each study visit comprised blood sampling, physical examination, and taking the patient's history of clinical events or changes in medication since the last study visit. On day 28 (if already discharged) and day 90 the patient was contacted by the investigator to evaluate the vital and transplant status.
DATA MANAGEMENT AND LABORATORY PARAMETERS
The clinical data of all patients were collected by the CANONIC study team, as described. Crea, CysC, and NGAL were determined using reagents from Beckman Coulter, Biomed, and Bioporto, respectively. All assays were run according to the manufacturers' protocols on automated clinical chemistry analyzers from Beckman Coulter (AU 680 and AU 5800). The intra-assay and interassay variabilities were as follows: Crea, (intra) 1.2%, (inter) 2.0%; NGAL, (intra) 1.2%, (inter) 1.5%; CysC, (intra) 1.8%, (inter) 1.4%.
The estimated GFR (eGFR) was calculated by two different equations: Cys-eGFR (32) and Chronic Kidney Disease Epidemiology Collaboration incorporating Crea and CysC (CKD-EPI-Crea-Cys). (33) ACLF was diagnosed using the established definition criteria of Moreau et al. (1) RD was defined as Crea 1.5 mg/dL, according to the criteria of ACLF and the chronic liver failure-sequential organ failure assessment score. The presence or absence of HRS was stated by the study investigator.
STATISTICAL ANALYSIS
Data were collected by the CANONIC investigator team using an electronic case report form. Values of NGAL, CysC, and Crea were directly entered into a data sheet. Quantitative variables were expressed as mean and standard deviation or median and interquartile range, where appropriate. They were compared using the Student t test or the Mann-Whitney U test, respectively. Categorical variables were expressed as proportions and compared by the chi-squared test/ Fisher exact test.
Parameters found to be significantly associated with development of RD, HRS, or ACLF were tested in a logistic regression model (previously log-transformed, if needed) for their potential to predict the corresponding outcome. In order to compare the predictive value of parameters at baseline versus day 3, for these analyses we selected patients who did not develop ACLF, RD, or HRS within the first 3 days after inclusion. Multivariate logistic regression analyses included independent variables with statistically significant results in the univariate analyses. The variables were logtransformed before they were entered in logistic models. This could not be done for deltas of day 3 minus baseline values because they could result negative. The accuracy of prediction was compared by estimating the area under the receiver operating characteristic curve (AUROC). Regarding the prediction of 90-day mortality, we used a competing risk approach under the subdistribution hazard model with transplantation regarded as a competing event. The prediction accuracy in these models was compared by assuming normality of C indexes. Receiver operating characteristic analyses were performed to determine the best mathematical cutoff value of CysC for the prediction of ACLF, RD, and HRS development as well as 90-day mortality. Because each best cutoff value was close to CysC 5 1.5 mg/L, sensitivities and specificities were calculated with this predefined, best collective cutoff value.
Tests were considered statistically significant at a two-sided P < 0.05.
Results
DESCRIPTION OF STUDY POPULATION AT ENROLLMENT
The 429 patients included in the current study had a mean age of 56.3 (611.8) years, and 63.4% were male (Table 1) . At enrollment 176 patients (41.0%) had ACLF and 147 (34.3%) had RD defined as serum Crea 1.5 mg/dL. HRS was present in 34 of 428 patients (7.9%; 1 patient without information for HRS at enrollment).
As expected, patients with ACLF at inclusion had higher Model for End-Stage Liver Disease (MELD) and Child-Pugh scores than patients without ACLF. All tested markers of renal function, Crea, CysC, and NGAL, were lower in the non-ACLF group (Table  2) . Similar results were found regarding patients with or without RD at inclusion. Levels of CysC and NGAL were increased in cases of RD with a high significance, proving their reliability in patients with decompensated cirrhosis (Table 2) . When the ACLF group was separated into the three different grades of ACLF (Table 3) , we found an increase of several parameters for each higher grade of ACLF, for example, in MELD score, C-reactive protein level, and proportion of patients with infections at baseline. Regarding renal markers, all grades of ACLF had higher levels than the non-ACLF group.
CYSC, NGAL, AND CREA AS PREDICTORS OF CLINICAL DETERIORATION
Development of ACLF
To investigate the potential role of renal markers in predicting ACLF, we focused on the 209 patients without ACLF at the time of inclusion and with appropriate follow-up. Sixty-nine patients developed ACLF during follow-up, and 140 did not. There were no significant differences between the groups regarding age and sex (Table 4) . Baseline levels of Crea, CysC, and NGAL were higher in the group with development of ACLF. We found further baseline parameters that were significantly different between patients with later development of ACLF and without (Supporting Table S1 ). For example, the eGFR equations CysteGFR and CKD-EPI-Crea-Cys showed a decreased baseline eGFR in patients with ACLF development (P < 0.01 for both). On the contrary, the proportion of patients presenting with acute kidney injury (AKI) at the time of inclusion was not significantly different between the groups. Analyzing the deltas of day 3 -baseline of Crea, CysC, and NGAL, we found that deltas of CysC and Crea were not significantly higher in the group of patients with ACLF development.
We then determined the potential of each renal marker at baseline and of CysC at day 3 to predict development of ACLF using a logistic regression model. The odds ratios (ORs) at baseline for Crea, CysC, and NGAL were 3.5 (95% confidence interval [CI], 0.9-13.5), 5.9 (95% CI, 1.3-26.0), and 1.5 (95% CI, 0.8-2.8) respectively, suggesting that only CysC is a significantly predictive factor (Fig. 1) . The corresponding AUROC of baseline CysC was 0.68 (95% CI 0.55-0.82). Multivariate logistic regression demonstrated baseline CysC as an independent predictor. With the predefined cutoff value of 1.5 mg/L, the development of ACLF was predicted by CysC with 58.0% sensitivity and 66.4% specificity. The day 3 value of CysC was a significant predictor of ACLF development, too (OR, 4.6; 95% CI, 1.1-19.9; AUROC, 0.63; 95% CI 0.48-0.79). AUROC comparison between day 3 CysC and baseline CysC showed no significant difference (Supporting Table S2 ). Moreover, the tested eGFR equations were found to be significant predictors of ACLF development. However, prediction accuracy of baseline CysC was not inferior to those of the two tested eGFR equations.
Development of RD
Out of the study population, 197 patients without RD at baseline, defined as Crea <1.5 mg/dL, had samples available for follow-up analysis. Approximately 14% of them (27 of 197) developed RD during followup. There were no significant differences in age, sex, or MELD score compared to patients who did not develop RD (Table 5 ). However, the baseline markers of renal function showed significantly higher values in the group of patients with development of RD. Moreover, significant differences between the groups were found regarding the proportion of patients with AKI at enrollment, the eGFR, and the delta day 3 -baseline values of Crea, CysC, and NGAL, respectively (Supporting Table S1 ). Regarding the baseline values of NGAL and CysC at enrollment, only the latter turned out to be predictive of RD development (NGAL OR, 1.6; 95% CI 0.9-3.1; CysC OR, 9.4; 95% CI, 1.8-49.6) (Fig. 1) . Crea was not used in a logistic regression model because RD is defined by Crea values. With 1.5 mg/L as a cutoff value, development of RD was predicted by CysC with 63.0% sensitivity and 73.5% specificity. The ORs of the eGFR equations using CysC were significantly lower than 1, so both equations were predictors of RD development. By AUROC analyses we found no significant difference in prediction accuracy compared to baseline CysC (Supporting Table S2 ).
Development of HRS
To investigate which parameters are associated with the development of HRS, we focused on the 394 patients who did not have HRS at inclusion. Fortytwo of them exhibited HRS during follow-up, whereas 350 did not (data of 2 patients missing). Baseline characteristics of both groups are shown in Table 6 . Baseline values of Crea, CysC, as well as NGAL were significantly higher in patients with HRS development (P < 0.0001 for all). Moreover, values of eGFR equations were significantly lower in patients with HRS development (P < 0.0001 for all) (Supporting Table  S1 ). The delta day 3 -baseline values of Crea, CysC, and NGAL were not significantly different between patients with and without HRS development (Table 6) .
CysC baseline values were predictive of HRS development (OR, 4.2; 95% CI, 1.2-12.8; AUROC 0.71; 95% CI 0.60-0.83), whereas those of NGAL and Crea were not (Fig. 1) . In a multivariate analysis after adjusting for other clinical parameters, CysC was shown to be an independent predictor of HRS development. The eGFR equations as well as CysC of day 3 were significant predictors but not superior compared to baseline CysC (Supporting Table S2 ). CysC at a cutoff at 1.5 mg/L yielded a sensitivity and specificity of 83.3% and 51.7%, respectively.
CYSC, NGAL, AND CREA AS PREDICTORS OF MORTALITY
The overall 90-day mortality rate was 27.6% (116/ 421). A total of 49 patients underwent transplantation; hence, the transplant-free survival rate was 61.0% (1 patient died after transplantation during follow-up).
Baseline characteristics at inclusion showed that many variables, such as MELD score and presence of ACLF, were significantly associated with 90-day mortality. Regarding markers of renal function, baseline values of all three, Crea, CysC, and NGAL, were remarkably higher in patients who died within 90 days (P < 0.0001 for all markers) ( Table 7) . Similarly, all eGFR equations and the presence of AKI were significantly associated with 90-day mortality as well. In contrast, delta day 3 -baseline values of Crea, CysC, and NGAL were not significantly higher in the nonsurvivor group.
By competing risk approaches all renal markers at baseline were shown to be predictors of 90-day mortality. The hazard ratios of Crea, CysC, and NGAL were 2.2 (95% CI 1.6-3.0), 3.1 (95% CI 2.1-4.7), and 1.9 (95% CI 1.5-2.3), respectively. In a multivariate analysis, after adjusting for other clinical parameters, each was found to be an independent predictor. The prediction accuracies of Crea, CysC, and NGAL were not significantly different. Furthermore, we compared the C indexes of the eGFR equations, also predictors of 90-day mortality, to CysC and found no significant difference in the prediction accuracy (Supporting Table S3 ). A CysC cutoff value of 1.5 mg/L was found to predict 90-day mortality with 73.3% sensitivity and 52.5% specificity.
Discussion
The current study was performed to investigate the prognostic role of CysC and NGAL, two novel markers of renal function, in the setting of acutely decompensated liver cirrhosis. We analyzed the data of 429 patients who were hospitalized due to acute decompensation of liver cirrhosis and included in the CANONIC trial. The main findings are that both CysC and NGAL were significant predictors of 90-day mortality. However, only CysC, and not NGAL, was found to independently predict RD, HRS, and ACLF development.
It is well known that Crea as a marker of renal function has several relevant limitations in patients with liver cirrhosis. (34) Still, it is generally used because there are no established alternatives so far. In recent years CysC and NGAL have been suggested as valuable novel plasma biomarkers.
Besides markers in blood, several proteins have been evaluated in urine as potential biomarkers in cirrhosis, for example, KIM-1, interleukin-18, and NGAL. (19) Urinary NGAL, an indicator of tubular damage, has been proposed as a biomarker of RD in liver cirrhosis. (35) Recent data suggest NGAL in urine as a predictor of ACLF as well as of mortality. (31, 36) However, there are some issues regarding urinary NGAL, the most relevant being that urinary NGAL concentrations increase in patients with urinary tract infections. (37) Therefore, the current study investigated NGAL and CysC in blood plasma.
We analyzed a large cohort of patients admitted due to acute decompensation of cirrhosis. Hence, our study provides a realistic image of the clinical situation. A proportion of 34% of all patients already had RD at the time of inclusion; 41% had ACLF. In both groups we found a significant elevation of plasma levels of CysC as well as of NGAL.
Development of ACLF dramatically increases the probability of short-term mortality in acutely decompensated cirrhosis. Therefore, it could be very helpful to identify patients who do not exhibit ACLF but are at high risk of developing ACLF. This could influence treatment decisions, such as admission to an intensive care unit or evaluation for liver transplantation. We analyzed whether CysC or NGAL could predict development of RD, HRS, ACLF, and mortality.
Comparing baseline parameters of patients with and without development of RD revealed some remarkable differences. Paradoxically we found that fewer patients with development of RD had infections at the time of inclusion (11.1% versus 31.2%; P 5 0.03); accordingly, an early infection seems to protect patients from renal deterioration, maybe due to better adaptation of the immune response. Significant differences between the groups were shown with respect to the plasma levels of Crea, CysC, and NGAL, which were markedly lower in patients without development of RD. However, only CysC, but not NGAL, was found to be predictive for RD development. Similar results were obtained with respect to the development of HRS. Baseline levels of all three, Crea, CysC, and NGAL, were significantly higher in the group of patients who were about to develop HRS during follow-up (P < 0.0001 for all). Again, CysC was the only independent predictor.
Regarding ACLF development, interestingly neither C-reactive protein, leukocyte count, nor the proportion of patients with an infection at inclusion differed among the groups. Thus, based on our data, an infection or inflammation seems not to predict development of ACLF. In terms of renal markers, we found that all three significantly increased in the group with ACLF development. Logistic regression revealed only CysC as an independent predictive factor for ACLF. In accordance with Ariza et al., (31) plasma NGAL did not predict ACLF development.
At 90 days after inclusion 116 of 421 patients were deceased. Comparing the baseline parameters of both groups revealed significantly higher concentrations of Crea, CysC, and NGAL in the nonsurvivor group (P < 0.0001 for all). Furthermore, the baseline values of all three markers were predictive for 90-day transplant-free mortality. Remarkably, Ariza et al. found plasma NGAL not to be predictive of short-time mortality. (31) However, in contrast to Ariza et al., who selected patients according to the availability of urine samples, we analyzed only patients of the CANONIC population, who had a continuous follow-up surveillance during hospitalization. Hence, even though patients of both studies were recruited from the same population, they are different, which may explain some diversity in the results.
In 2012 a new eGFR equation, CKD-EPI-CreaCys, based on Crea and CysC, was published and subsequently validated in patients with liver cirrhosis. (23, 33, 38) It was shown to reflect renal function more precisely than previous eGFR equations. Therefore, we investigated the predictive potential of this equation in our study population. We additionally tested an equation based on CysC only (Cys-eGFR). (32) In the present study, both eGFR equations were significant predictors of ACLF, RD, and HRS development, as well as of 90-day mortality. However, none of them had better prediction accuracy than CysC alone.
Recently, the concept of AKI was introduced in cirrhosis. The definition of AKI was adapted from the Acute Kidney Injury Network criteria. Rather than the absolute Crea concentration, it takes into account its relative changes. AKI has been described as a predictor of mortality in patients with liver cirrhosis. (39, 40) The reason for primarily focusing on RD defined by a Crea cutoff of 1.5 mg/dL, instead of AKI, in the CANONIC protocol and in our study was that RD is part of the definition of ACLF as well as part of the chronic liver failure-sequential organ failure assessment score. However, we also determined the presence of AKI in our study population. AKI was a significant predictor of 90-day mortality. Because AKI is dichotomous in nature, an AUROC comparison to CysC regarding the predictive value was not possible. Remarkably, the presence of AKI was not significantly associated with the development of ACLF.
Recent studies on risk scores in patients with cirrhosis showed that calculations at day 3 had better predictive values than using baseline data. (41, 42) One could hypothesize that an increase of renal markers within the first 3 days after inclusion could be a strong predictor of clinical deterioration as well as mortality. Therefore, we compared the prediction accuracy of baseline CysC to CysC at day 3 but found no significant differences. Similarly, calculating the deltas of day 3 minus baseline of Crea, CysC, and NGAL did not provide any benefit. Thus, waiting 2 or more days seems of no benefit to improve CysC prediction of relevant deterioration.
In conclusion, the current study proves the potential of CysC as a valuable biomarker in patients with decompensated liver cirrhosis. We demonstrate that the baseline value of CysC is a predictor of the development of RD, HRS and ACLF, as well as of 90-day transplant-free mortality. Moreover, the predictive accuracy of CysC was not inferior to that of Crea and/ or the CysC-based eGFR equations. CysC 1.5 mg/L was found to be the best collective cutoff value with a good sensitivity for all events, e.g., > 80% sensitivity for HRS. Even though plasma NGAL was also associated with some of the above-mentioned events, the results of the current study indicate a superiority of CysC in most aspects. Hence, CysC may help in the early identification of patients at risk of deterioration and might improve clinical management.
